BIAF

bioAffinity Technologies, Inc.
CAPPED RATING

bioAffinity Technologies, Inc. (BIAF) is rated C- (2.0/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Momentum (F).

Quantitative Factor Evaluation • Updated

Overall Rating
2.0 / 5.0
C-
Value
B-
Factor Score 3.0 / 5.0
Growth
D
Factor Score 1.2 / 5.0
Profitability
C+
Factor Score 2.8 / 5.0
Momentum
F
Factor Score 0.5 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -3.3
EV / EBITDA -0.2
Rev Growth YoY -26.0%
Gross Margin 27.0%
Price Return 3M -71.8%
Price Return 12M -92.9%
Catalyst Signal 0.00
Market Cap $3.6M
TTM Revenue $5.5M
Price / Sales 0.7
ROE -240.5%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 B- (3.0) D (1.2) C+ (2.8) F (0.5) C+ (2.6) C- (2.0)
2026-11-10 B- (3.0) C+ (2.6) C+ (2.6) F (0.5) C+ (2.6) C (2.3)
2026-11-03 B- (3.0) C+ (2.6) C+ (2.7) F (0.6) C+ (2.7) C (2.3)
2026-10-27 B- (3.0) C+ (2.6) C+ (2.7) F (0.5) C+ (2.6) C (2.3)
2026-10-20 B- (3.0) C+ (2.6) C+ (2.7) F (0.5) C+ (2.6) C (2.3)
Page 1 of 4